Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Vymada holds a significant presence in India, with annual sales of around ₹550 crore. The Indian Patent Office’s decision to revoke Novartis’ patent, citing lack of novelty and technical advancement, is set to reshape the ₹550 crore market. This move is expected to open the floodgates for generics, potentially reducing prices by over 70% and improving access for millions of cardiovascular patients across the country.